

Supplementary Information

B cell development is critically dependent on NFATc1 activity

Sabrina Giampaolo¹, Gabriela Wójcik², Stefan Klein-Hessling^{1,3}, Edgar Serfling^{1,3} & Amiya K. Patra^{1,2}

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure S1. NFATc1 expression at different stages of B cell development. (a)

Immunofluorescence analysis of NFATc1, NFATc2 and NFATc3 expression in B220⁺IL-7R⁺ pro-B and B220⁺IL-7R⁻ pre-B cells from WT mice. **(b)** Quantification of nuclear NFATc1 (pro-B; $n = 21$ and pre-B; $n = 34$), NFATc2 (pro-B; $n = 14$ and pre-B; $n = 34$) and NFATc3 (pro-B; $n = 17$ and pre-B; $n = 35$) levels in WT pro- and pre-B cells. **(c)** Mean fluorescence intensity (MFI) of GFP levels in B220⁺CD19⁺IgM⁻c-Kit⁺ pro-B, B220⁺CD19⁺IgM⁺CD25⁺ pre-B, B220⁺CD19⁺IgM⁺IgD⁻ immature B and B220⁺CD19⁺IgM⁺IgD⁺ mature B cells in the bone marrow from *Nfatc1-eGfp-Bac* tg mice. **(d)** GFP expression representing NFATc1 levels in B220⁺CD19⁺IgM⁺IgD⁻, B220⁺CD19⁺IgM⁺IgD⁺ and B220⁺CD19⁺IgM⁺IgD⁺ splenic B cells from WT and *Nfatc1-eGfp-Bac* tg mice. Numbers inside each histogram represent MFI. Data are representative of three independent experiments and are shown as mean $\pm$ s.d., unpaired *t*-test.

Supplementary Figure S2. Defective B cell development and B cell-specific gene expression

in absence of IL-7 signaling. (a) B220⁺CD43⁺CD24⁻BP1⁻ pre-pro-B, B220⁺CD43⁺CD24⁺BP1⁻ pro-B and B220⁺CD43⁺CD24⁺BP1⁺ large pre-B cells distribution in the BM from *Il7r^{-/-}* and *Il7^{-/-}* mice compared to WT controls. **(b)** RT-PCR analysis revealing expression levels of B cell development-specific transcription factors and pre-BCR-associated molecules in pro-B cells from *Il7^{-/-}* mice compared to WT mice. Data represent one of three independent experiments ($n = 4$ per group per experiment).

Supplementary Figure S3. Normal development of B cells in *Vav-CreNfatc1P2^{fl/fl}* mice. (a)

Quantification of percent B220⁺ cells distribution and of total B220⁺ B cells in the BM and spleen of *Vav-CreNfatc1P2^{fl/fl}* mice compared to WT littermates. **(b)** Quantification of percent

distribution and total cell numbers of IgM⁺, IgD⁺, IgM⁺IgD⁺, CD21⁺CD23⁻ and CD21⁺CD23⁺ cells in the spleen of *Vav-CreNfatc1P2^{fl/fl}* mice compared to WT littermates. Data represent one of three independent experiments ($n = 3$ per group), and are shown as mean $\pm$ s.d., paired t -test, ns = not significant.

Supplementary Figure S4. Defective B cell development in *Vav-CreNfatc1 α A^{fl/fl}* mice. (a) Quantification of percent distribution and total cell numbers of B220⁺ B cells in the BM and spleen of *Vav-CreNfatc1 α A^{fl/fl}* mice compared to WT littermates. (b) Quantification of percent distribution and total cell numbers of IgM⁺, IgD⁺ and IgM⁺IgD⁺ cells in the BM and spleen of *Vav-CreNfatc1 α A^{fl/fl}* mice compared to WT littermates. (c) Quantification of percent distribution and total cell numbers of CD21⁺CD23⁻ and CD21⁺CD23⁺ cells in the spleen of indicated mice. (d) Quantification of percent distribution and total cell numbers of splenic IgM⁻CD5⁺ cells in the spleen of *Vav-CreNfatc1 α A^{fl/fl}* mice compared to WT littermates. (e) Quantification of percent distribution and total cell numbers of B220⁺CD19⁺IgM⁻CD25⁺ pre-B cells in the BM of indicated mice. Data represent one of three independent experiments ($n = 3$ WT and 4 *Vav-CreNfatc1 α A^{fl/fl}* mice), and are shown as mean $\pm$ s.d., unpaired t -test.


Supplementary Figure S5. NFATc1 activity is critical for B cell development in bone marrow. (a) Schematic diagram showing the involvement of NFATc1 upon IL-7 signaling in regulating EBF1 expression. EBF1 in turn regulates Pax5 expression essential for B cell differentiation and lineage maintenance. EBF1, Pax5 and E2A activity is critical for the differentiation of pro-B cells to pre-B cell and later stages. (b) Model showing the essentiality of a threshold level of NFATc1 activity in B cell development. Either deficiency or supra-physiological NFATc1 activity is detrimental for BM B cell differentiation and will invariably lead to the development of severe B cell lymphopenia.

Supplementary Table 1
LIST OF RT-PCR and ChIP PRIMERS

Gene	Primer Sequence	Product Size
<i>Actb</i>	For: 5'- CCAGGTCATCACTATTGGCAAGGA -3' Rev: 5'- GAGCAGTAATCTCCTTCTGCATCC -3'	223 bp
<i>Calcineurin</i>	For: 5'- AAGGAGGGAAGGCTGGAAGA -3' Rev: 5'- GGCATCCATACAGGCATCAT -3'	608 bp
<i>Cd19</i>	For: 5'- CTCCTCTCCCTGTCTCCTTC -3' Rev: 5'- CCACTATCCTCCACGTTTAC -3'	350 bp
<i>Cd79a</i>	For: 5'- AACCACAGGGGCTTGTACTG -3' Rev: 5'- CCCCTGGAGATGTCCTCATA -3'	318 bp
<i>Cd79b</i>	For: 5'- TCCAGACCCTCCTCATCATC -3' Rev: 5'- TATCCAGGAAGCAGGGAATG -3'	284 bp
<i>Dnmt</i>	For: 5'- CTCCCAGAATGTTCCAGC -3' Rev: 5'- ATGGGGAATGGCAGAGAT -3'	204 bp
<i>Ebfl</i>	For: 5'- TGC GGAAATCCA ACTTCTTC -3' Rev: 5'- GGTTCTTGTCTTGGCCTTCA -3'	257 bp
<i>Ebfla</i>	For: 5'- AGAGGGCCTTTGAGCTTAGG -3' Rev: 5'- AAAAGAGGGGATGGCTTTTG -3'	240 bp
<i>Ebflb</i>	For: 5'- CCCTCCTTGTTATCGCTCAG -3' Rev: 5'- CCTGGATCCCAAACATGAAA -3'	221 bp
<i>Foxo1</i>	For: 5'- CTGCCAGTCTGTCTGAAAT -3' Rev: 5'- GGGGAGGAGAGTCAGAAGTC -3'	345 bp
<i>Id1</i>	For: 5'- CCAGTGGGTCTCATCCCTTA -3' Rev: 5'- AGAAATCCGAGAAGCACGAA -3'	368 bp
<i>Id2</i>	For: 5'- ACTCGCATCCCACTATCGTC -3' Rev: 5'- TCCCCATGGTGGGAATAGTA -3'	453 bp
<i>Id3</i>	For: 5'- CTTGGCGGTCTGTTTTGAAT -3' Rev: 5'- GTCAGTGGCAAAGCTCCTC -3'	494 bp
<i>Igll1 (λ5)</i>	For: 5'- GAGCTTCAGTGGGAAGCAAC -3' Rev: 5'- GGGTAGAATTTCGCTACCAA -3'	268 bp
<i>Il7r</i>	For: 5'- AAAGCATGATGTGGCCTACC -3' Rev: 5'- CAGGAACTTTCGGGATTGA -3'	427 bp
<i>Jak3</i>	For: 5'- ACTGGCGGGACTTATCACAC -3' Rev: 5'- GAAGTCCCTCTGCTGGTCTG -3'	352 bp
<i>Nfkb1</i>	For: 5'- GTGGAGGCATGTTCCGTTAGT -3' Rev: 5'- CCAAGTGCAGAGGTGTCTGA -3'	609 bp
<i>Nfatc1</i>	For: 5'-GACTTCGATTTCTCTTCGAGTTC-3' Rev: 5'-CTCGATTCTCGGACTCTCCAG-3'	297 bp
<i>Nfatc1 α:</i> (P1 activity)	For: 5'-GGGAGCGGAGAACTTTGC-3' Rev: 5'-GATCTCGATTCTCGGACTCTCC-3'	319 bp
<i>Nfatc1 β:</i> (P2 activity)	For: 5'-CGACTTCGATTTCTCTTCGAG -3' Rev: 5'- GATCTCGATTCTCGGACTCTCC-3'	311 bp
<i>Nfatc2</i>	For: 5'-GGGTTCGGTGAGTGACAGTT-3' Rev: 5'-CTCCTTGGCTGTTTGGGATA-3'	371 bp
<i>Nfatc3</i>	For: 5'-CCGATGACTACTGCAAACGTGG-3' Rev: 5'-TTTGAATACTTGGGCACTCAAAGG-3'	343 bp


<i>Notch1</i>	For: 5'- TTGACGTCACCTCTCCTGTGC -3' Rev: 5'- ACACAGGTGCCATTGTTGAA -3'	408 bp
<i>Notch2</i>	For: 5'- ACCCTTGTATGCACGGAGTC -3' Rev: 5'- CCAGGTTATTGCACGTTTCCT -3'	373 bp
<i>Notch3</i>	For: 5'- GCACCTGCAACCCTGTTTAT -3' Rev: 5'- TCTCCAGCATCACCACAGAG -3'	370 bp
<i>Oct1</i>	For: 5'- TTCAGTGCAGTCAGCCATTC -3' Rev: 5'- GGCTTTGCTGAGGTAGTTGC -3'	425 bp
<i>Oct2</i>	For: 5'- GGAGCTGGAACAGTTTGCTC -3' Rev: 5'- GATGCTGGTCCTCTTCTTGC -3'	310 bp
<i>Pax5</i>	For: 5'- GGGCTCCTCATACTCCATCA -3' Rev: 5'- CGTCAAGTTGGCTTTCATGT -3'	321 bp
<i>Plcg2</i>	For: 5'- CAAGAGAGCGCTGGAGTTAG -3' Rev: 5'- TCAAACCAGAGAGCCACTTC -3'	327 bp
<i>Rag1</i>	For: 5'- ACCATGTGTCAAGCCACAAA -3' Rev: 5'- TGGCTACAGCTGAGGAAGGT -3'	332 bp
<i>Rag2</i>	For: 5'- TCTCTAAAGATTCTGCTACCTC -3' Rev: 5'- TGGAATTCAGTCTGGGGTAC -3'	563 bp
<i>RelA</i>	For: 5'- GACCATGGACGATCTGTTTC -3' Rev: 5'- CGTGAAAGGGGTTATTGTTG -3'	431 bp
<i>RelB</i>	For: 5'- GACAAGGTGCAAAAAGAGGA -3' Rev: 5'- GATTCCATGTGGATCAGAGC -3'	315 bp
<i>Spil</i>	For: 5'- CGGATGACTTGTTACTTACG -3' Rev: 5'- GTAGGAAACCTGGTGACTGAG -3'	292 bp
<i>Stat5a</i>	For: 5'- ACTGTTCAACATCAGCAGCA -3' Rev: 5'- TTCAGATTCCAGAGGTTTCG -3'	327 bp
<i>Stat5b</i>	For: 5'- ACTGTTCAACATCAGCAGCA -3' Rev: 5'- AGGCATCAGATTCCAAAACA -3'	328 bp
<i>Tcf12</i>	For: 5'- ATTTATTCCCCTGACCACAC -3' Rev: 5'- GTAGCACATGGATAGCATCA -3'	281 bp
<i>Tcf3</i>	For: 5'- GATCTACTCCCCGGATCACT -3' Rev: 5'- GGCATGGTTATGCAAAAGAC -3'	375 bp
<i>Vpreb</i>	For: 5'- GAACCTGGGGTATCTGAGCA -3' Rev: 5'- CTCATAGCAACACCGCAGAA -3'	296 bp
ChIP Primers		
<i>Ebfl</i>	For: 5'- AGGAAAGAAACATCTTTGGTT -3' Rev: 5'- TTTGTAGTAATCACAGGCCG -3'	235 bp

Supplementary Figure S1




Supplementary Figure S2

a




b




Supplementary Figure S3


a



b




Supplementary Figure S4



Supplementary Figure S5

a



b

